For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Golimumab - Inflammatory bowel disease
PAD Profile : Golimumab - Inflammatory bowel disease Important
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Azathioprine
- Infliximab
- Mercaptopurine
- Ciclosporin
- Vedolizumab
- Allopurinol
- Balsalazide sodium
- Prednisolone
- Budesonide
- Tofacitinib
- Methotrexate
- Mesalazine (Systemic)
- Filgotinib
- Sulfasalazine
- Upadacitinib
- Risankizumab
- Olsalazine sodium
Other Indications
- Ankylosing spondylitis
- Any paediatric use
- Psoriatic arthritis
- Rheumatoid arthritis
- Non-radiographic axial spondyloarthritis
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.
The PCN recommends the sequential use of TNF alpha inhibitors (adalimumab, infliximab or golimumab) in patients with moderately to severely active ulcerative colitis prior to a switch to vedolizumab.
Adalimumab, Infliximab and Golimumab are payment by results excluded drugs and will be considered RED on the traffic light system.
Gastroenterology specialists will be required to complete blueteq initiation and continuation forms for the commissioners.